Last updated on August 2019

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)


Brief description of study

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Only China and South Korea will remain open to recruiting.

Clinical Study Identifier: NCT03033511

Find a site near you

Start Over

CHU Charleroi (Vesale) /ID# 159008

Montigny-le-tilleul, Belgium
9.86miles
  Connect »